Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of pyrotinib combined with
trastuzumab and abraxane in HER2-positive MBC with brain metastasis.